JP4852211B2 - 原核生物における必須遺伝子の同定 - Google Patents

原核生物における必須遺伝子の同定 Download PDF

Info

Publication number
JP4852211B2
JP4852211B2 JP2001569338A JP2001569338A JP4852211B2 JP 4852211 B2 JP4852211 B2 JP 4852211B2 JP 2001569338 A JP2001569338 A JP 2001569338A JP 2001569338 A JP2001569338 A JP 2001569338A JP 4852211 B2 JP4852211 B2 JP 4852211B2
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
polypeptide
cell
gene product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001569338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516805A5 (OSRAM
JP2004516805A (ja
Inventor
ハセルベック，ロバート
エル． オールセン，カリ
ダブリュ． ザイスカインド，ジュディス
ウォール，ダニエル
ディー． トラウィック，ジョン
ジェイ． カー，グラント
ティ． ヤマモト，ロバート
スー，エイチ．ハワード
フォーシス，アール．アリン
Original Assignee
メルク アンド カンパニー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク アンド カンパニー インコーポレイテッド filed Critical メルク アンド カンパニー インコーポレイテッド
Publication of JP2004516805A publication Critical patent/JP2004516805A/ja
Publication of JP2004516805A5 publication Critical patent/JP2004516805A5/ja
Application granted granted Critical
Publication of JP4852211B2 publication Critical patent/JP4852211B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001569338A 2000-03-21 2001-03-21 原核生物における必須遺伝子の同定 Expired - Fee Related JP4852211B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US19107800P 2000-03-21 2000-03-21
US60/191,078 2000-03-21
US20684800P 2000-05-23 2000-05-23
US60/206,848 2000-05-23
US20772700P 2000-05-26 2000-05-26
US60/207,727 2000-05-26
US24257800P 2000-10-23 2000-10-23
US60/242,578 2000-10-23
US25362500P 2000-11-27 2000-11-27
US60/253,625 2000-11-27
US25793100P 2000-12-22 2000-12-22
US60/257,931 2000-12-22
US26930801P 2001-02-16 2001-02-16
US60/269,308 2001-02-16
PCT/US2001/009180 WO2001070955A2 (en) 2000-03-21 2001-03-21 Identification of essential genes in prokaryotes

Publications (3)

Publication Number Publication Date
JP2004516805A JP2004516805A (ja) 2004-06-10
JP2004516805A5 JP2004516805A5 (OSRAM) 2008-04-24
JP4852211B2 true JP4852211B2 (ja) 2012-01-11

Family

ID=27569239

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001569338A Expired - Fee Related JP4852211B2 (ja) 2000-03-21 2001-03-21 原核生物における必須遺伝子の同定

Country Status (7)

Country Link
US (1) US20020061569A1 (OSRAM)
EP (1) EP1268774A2 (OSRAM)
JP (1) JP4852211B2 (OSRAM)
KR (1) KR20020097200A (OSRAM)
AU (1) AU2001249345A1 (OSRAM)
CA (1) CA2404260A1 (OSRAM)
WO (1) WO2001070955A2 (OSRAM)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503619A (ja) * 1996-01-19 1999-03-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー スタフィロコッカス・アウレウスのメチオニル−ｔＲＮＡシンセターゼ
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
JP2003506011A (ja) * 1999-04-15 2003-02-18 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア ソーターゼ遺伝子の同定
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
US7125698B2 (en) * 1999-08-09 2006-10-24 Matthew Glenn Polynucleotides, materials incorporating them, and methods for using them
CA2386235A1 (en) * 1999-10-04 2001-04-12 Merck & Co., Inc. Mray gene and enzyme of pseudomonas aeruginosa
US6861516B1 (en) 1999-10-04 2005-03-01 Merck & Co., Inc. MraY gene and enzyme of pseudomonas aeruginosa
US20020120408A1 (en) * 2000-09-06 2002-08-29 Kreiswirth Barry N. System and method for tracking and controlling infections
US7349808B1 (en) 2000-09-06 2008-03-25 Egenomics, Inc. System and method for tracking and controlling infections
WO2002034771A2 (en) 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
DK1355918T5 (da) 2000-12-28 2012-02-20 Wyeth Llc Rekombinant beskyttelsesprotein af streptococcus pneumoniae
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002307448A1 (en) * 2001-04-20 2002-11-05 President And Fellows Of Harvard College Methods and compositions for the modulation of biofilm formation
AU2002328215A1 (en) * 2001-09-18 2003-04-01 Affinium Pharmaceuticals, Inc. Purified bacterial polypeptides involved in nucleic acid processing
AU2002328225A1 (en) * 2001-09-21 2003-04-01 Affinium Pharmaceuticals, Inc. Bacterial polypeptides involved in protein processing
WO2003045985A2 (en) * 2001-11-26 2003-06-05 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in carbohydrate and coenzyme metabolism
AU2002331473A1 (en) * 2001-09-25 2003-04-07 Affinium Pharmaceuticals, Inc. Purified polypeptides from pseudomonas aeruginosa
WO2003029407A2 (en) * 2001-09-26 2003-04-10 Merck & Co., Inc. Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
EP1930420A1 (en) * 2001-09-26 2008-06-11 Merck & Co., Inc. Isolated nucleic acid molecules encoding a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
EP1456380B1 (en) * 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
RU2229513C2 (ru) 2001-11-23 2004-05-27 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" Способ получения l-аминокислот, штамм escherichia coli - продуцент l-аминокислоты (варианты)
AU2002364771A1 (en) * 2001-11-26 2003-06-10 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism as possible drug targets
TW200303919A (en) * 2001-12-05 2003-09-16 Hiroyuki Ohno Cytotoxic protein and the use
US20030170694A1 (en) * 2001-12-21 2003-09-11 Daniel Wall Stabilized nucleic acids in gene and drug discovery and methods of use
WO2003066849A2 (en) * 2002-02-04 2003-08-14 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from staphylococcus aureus
US6946267B2 (en) * 2002-03-13 2005-09-20 Dr. Chip Biotechnology Inc. Method for detecting Staphylococcus aureus
WO2003087353A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in membrane biogenesis
US20090252756A1 (en) * 2002-04-02 2009-10-08 Yaffa Mizrachi-Nebenzahl Protein-based streptococcus pneumoniae vaccines
US8691243B2 (en) 2002-04-02 2014-04-08 Ben-Gurion University Of The Negev Research And Development Authority Protein-based Streptococcus pneumoniae vaccine
AU2003213950A1 (en) * 2002-04-08 2003-10-27 Affinium Pharmaceuticals, Inc. Purified polypeptides from s. aureus, h. pylori and e. coli involved in cellular transport and metabolism
AU2003218563A1 (en) * 2002-04-09 2003-10-27 Affinium Pharmaceuticals, Inc. Enolase polypeptides and structures
AU2003218934A1 (en) * 2002-04-17 2003-11-03 Affinium Pharmaceuticals, Inc. Purified (3r)-hydroxymyristoyl-(acyl-carrier-protein) dehydratase polypeptide from pseudomonas aeruginosa
AU2003229205A1 (en) * 2002-05-31 2003-12-19 Affinium Pharmaceuticals, Inc. Bacterial polypeptides involved in viability
WO2003102544A2 (en) * 2002-05-31 2003-12-11 Cognosci, Inc. Assays for measuring matrix metalloproteinase activities
US20060035365A1 (en) * 2002-07-17 2006-02-16 Hamelin Michael J Method for identifying cellular growth inhibitors
WO2004013167A2 (en) * 2002-08-01 2004-02-12 Affinium Pharmaceuticals, Inc. Purified polypeptides from enterococcus faecalis
AU2003278714A1 (en) * 2002-08-20 2004-03-11 Chiron Corporation Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes
US20070053924A1 (en) * 2002-08-26 2007-03-08 Herve Tettelin Conserved and specific streptococcal genomes
AU2003280247A1 (en) * 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
FR2846668B1 (fr) * 2002-11-05 2007-12-21 Univ Aix Marseille Ii Identification moleculaire des bacteries du genre streptococcus et genres apparentes
AU2003280250A1 (en) * 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial thymidylate kinases
WO2004058812A2 (en) * 2002-12-26 2004-07-15 Affinium Pharmaceuticals, Inc. Ribose-phosphate pyrophosphokinase polypeptides and structures
WO2004081206A2 (en) * 2003-03-12 2004-09-23 Affinium Pharmaceuticals, Inc. Novel polypeptides encoded by essential bacterial genes
AU2003287825A1 (en) * 2002-12-31 2004-07-22 Affinium Pharmaceuticals, Inc. Crystal structures of nh3-dependent nad synthetases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7618775B2 (en) * 2003-04-17 2009-11-17 The Scripps Research Institute Expanding the eukaryotic genetic code
US20050026189A1 (en) * 2003-05-29 2005-02-03 Liangsu Wang Microbial operons
JP4875490B2 (ja) * 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
ATE520709T1 (de) 2003-09-19 2011-09-15 Epitopix Llc Campylobacter-polypeptide und verwendungsverfahren
US20050176033A1 (en) * 2003-11-10 2005-08-11 Klyachko Elena V. Mutant phosphoribosylpyrophosphate synthetase and method for producing L-histidine
WO2005108626A2 (en) * 2004-05-07 2005-11-17 Replidyne, Inc. Mutants of staphylococcal mrs and methods of use
JP2008507296A (ja) * 2004-07-26 2008-03-13 ナノスフェアー　インコーポレイテッド 混合培養物中でメチシリン耐性黄色ブドウ球菌とメチシリン感受性黄色ブドウ球菌とを区別する方法
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
US20060078952A1 (en) * 2004-09-14 2006-04-13 Carine Robichon Method for identifying antimicrobial molecules which interfere with apolipoprotein N-acyltransferase activity
US20080095792A1 (en) * 2004-09-17 2008-04-24 Anderson Annaliesa S Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus
CA2583803C (en) * 2004-10-08 2014-11-25 Giuliano Bensi Immunogenic and therapeutic compositions for streptococcus pyogenes
DE102004055508A1 (de) * 2004-11-17 2006-06-01 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
ES2589927T3 (es) 2005-01-21 2016-11-17 Merck Sharp & Dohme Corp. Polipéptidos para inducir una respuesta inmunitaria protectora contra Staphylococcus aureus
CN101142230A (zh) 2005-01-21 2008-03-12 埃皮托皮克斯有限责任公司 耶尔森氏菌属物种的多肽及其使用方法
AU2006214534B2 (en) 2005-02-14 2012-07-19 Epitopix, Llc Polypeptides from Staphylococcus aureus and methods of use
GB0505949D0 (en) 2005-03-23 2005-04-27 Univ Sheffield Polypeptides
NZ591415A (en) * 2005-03-30 2012-10-26 Novartis Vaccines & Diagnostic Haemophilus influenzae type B
WO2007093848A2 (en) * 2005-08-03 2007-08-23 Affinium Pharmaceuticals, Inc. Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
US8945899B2 (en) 2007-12-20 2015-02-03 Butamax Advanced Biofuels Llc Ketol-acid reductoisomerase using NADH
US7960312B2 (en) * 2005-11-10 2011-06-14 National University Of Corporation Hiroshima University Method and agent for immobilizing protein via protein bound to silicon oxide-containing substance
WO2007106536A2 (en) 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
ATE522541T1 (de) * 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
EP2074231B1 (en) * 2006-09-14 2010-06-16 Universitat De Girona A method for specific detection of salmonella spp
FR2906532B1 (fr) * 2006-09-28 2008-12-12 Biomerieux Sa Nouvel oligonucleotide marque
WO2008044599A1 (fr) * 2006-10-06 2008-04-17 Proteus Science Co., Ltd. Polypeptide ayant une activité de ciblage d'un intestin présentant une inflammation, et son utilisation
JP2010508276A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 化膿連鎖球菌のための免疫原性組成物および治療組成物
BRPI0808600A2 (pt) * 2007-04-18 2018-12-26 Du Pont "método para a conversão de acetolactato em dihidroxi-isovalerato, método para a produção de isobutanol, célula hospedeira recombinante e método para a identificação e isolameno de uma construção genética"
US8017337B2 (en) 2007-04-19 2011-09-13 Molecular Detection, Inc. Methods, compositions and kits for detection and analysis of antibiotic-resistant bacteria
JP2010183841A (ja) * 2007-05-29 2010-08-26 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
BRPI0821748A2 (pt) * 2007-12-19 2019-09-24 Basf Plant Science Gmbh método para produzir uma planta com rendimento aumentado, molécula isolada de ácido nucleico, construção de ácido nucleico, vetor, processo para produzir um polipeptídeo, polipeptídeo, anticorpo, núcleo de célula de planta, célula de planta, tecido de planta, material de propagação, semente, pólen, progênie, ou uma parte de planta, ou uma planta com rendimento aumento, processo para a indentificação de um composto, método para a produção de uma composição agrícola, composição, polipeptídeo ou molécula de ácido nucleico, uso dos ácidos nucléicos, e, método para a indentificação de uma planta com um rendimento aumentado
DK2235046T3 (da) * 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O
FI20075976A0 (fi) * 2007-12-31 2007-12-31 Finnzymes Oy Menetelmät ja oligonukleotidit utaretulehdusta aiheuttavien bakteerien osoittamiseksi
WO2009100215A2 (en) 2008-02-08 2009-08-13 Mayo Foundation For Medical Education And Research Detection of clostridium difficile
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
KR100975956B1 (ko) * 2008-08-08 2010-08-13 주식회사 콤슨테크놀러지 살균기능을 가지는 장애인용 이동장치
US8637249B2 (en) * 2008-11-14 2014-01-28 Gen-Probe Incorporated Compositions, kits and methods for detection of Campylobacter nucleic acid
JP2012509665A (ja) * 2008-11-26 2012-04-26 メルク・シャープ・エンド・ドーム・コーポレイション スタフィロコッカス・アウレウス（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対する防御免疫応答を誘導するポリペプチド
CN105582524A (zh) * 2009-03-23 2016-05-18 埃皮托皮克斯有限责任公司 多肽和含有革兰氏阳性多肽的免疫组合物及使用方法
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
MX341395B (es) 2010-03-23 2016-08-18 Novartis Ag * Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc.
KR101933226B1 (ko) 2010-05-05 2018-12-28 뉴욕 유니버시티 스타필로코커스 아우레우스 류코시딘, 치료 조성물 및 그것의 용도
SG186290A1 (en) 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
JP6048932B2 (ja) * 2010-12-28 2016-12-21 国立大学法人広島大学 酸化ケイ素と窒化ケイ素とを識別するポリペプチドおよびその利用
MX347976B (es) 2011-03-24 2017-05-22 Butamax(Tm) Advanced Biofuels Llc Celulas huesped y metodos para producir isobutanol.
WO2012136653A1 (en) * 2011-04-08 2012-10-11 Novvac Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
GB201116767D0 (en) 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
EP2773655A4 (en) * 2011-10-31 2015-04-22 Merck Sharp & Dohme PROTECTION BASED ON STAPHYLOCOCCUS AUREUS SA2074 PROTEIN
DK2812434T3 (en) 2012-02-09 2018-07-16 Bavarian Nordic As AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR-13 (TLR-13)
US9181568B2 (en) * 2012-04-23 2015-11-10 Exxonmobil Research And Engineering Company Cell systems and methods for improving fatty acid synthesis by expression of dehydrogenases
PL2844275T3 (pl) 2012-04-26 2021-03-08 University Of Chicago Koagulazy gronkowcowe stanowiące antygeny i sposoby ich zastosowania
WO2013176909A2 (en) 2012-05-11 2013-11-28 Butamax Advanced Biofuels Llc Ketol-acid reductoisomerase enzymes and methods of use
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
KR20150056540A (ko) * 2012-09-19 2015-05-26 노파르티스 아게 백신으로서의 클로스트리듐 디피실 폴리펩티드
US9512408B2 (en) 2012-09-26 2016-12-06 Butamax Advanced Biofuels Llc Polypeptides with ketol-acid reductoisomerase activity
NZ707035A (en) 2012-10-17 2018-11-30 Agronomique Inst Nat Rech Gene signatures of inflammatory disorders that relate to the liver
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
KR20150013092A (ko) * 2013-07-26 2015-02-04 삼성전자주식회사 숙신산 생산능이 향상된 박테리아 세포 및 이를 이용하여 숙신산을 생산하는 방법
CA2919383A1 (en) 2013-08-05 2015-02-12 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
US10100093B2 (en) 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
US20170049848A1 (en) * 2014-05-06 2017-02-23 Virginia Commonwealth University Target for Firmicutes and Related Bacteria: The PRP Protease
HRP20191671T1 (hr) 2014-05-09 2019-12-13 Immatics Biotechnologies Gmbh Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
FR3024903A1 (fr) 2014-08-14 2016-02-19 Biomerieux Sa Procede de quantification d'au moins un groupe de microorganismes par spectrometrie de masse
TWI649331B (zh) * 2015-06-11 2019-02-01 國立中興大學 鮑氏不動桿菌（Ａｃｉｎｅｔｏｂａｃｔｅｒ ｂａｕｍａｎｎｉｉ）多胜肽抗原及其抗體以及編碼該抗原之核酸
CN108368500B (zh) 2015-10-02 2023-05-26 犹他大学研究基金会 用于可调整核糖体翻译速度的组成物和使用方法
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
KR102050870B1 (ko) * 2017-04-06 2019-12-02 포항공과대학교 산학협력단 무항생제 플라스미드 유지 시스템에서 플라스미드 카피 수의 정량적 조절 방법
CN111867623B (zh) 2018-02-12 2024-06-04 英尼穆内公司 Toll样受体配体
US12018327B2 (en) 2018-03-01 2024-06-25 The Regents Of The University Of California Methods and compositions relating to epoxide hydrolase genes
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
CA3148183C (en) * 2019-08-28 2024-10-15 Inner Mongolia Eppen Biotech Co., Ltd. RECOMMENDED STRAIN BASED ON ESCHERICHIA COLI AND ITS CONSTRUCTION PROCESS AND APPLICATION
CA3153902A1 (en) 2019-10-16 2021-04-22 Pardis SABETI Engineered muscle targeting compositions
JP7471688B2 (ja) * 2019-12-03 2024-04-22 中國醫藥大學 オリゴペプチド、検出キット及び医薬組成物
US20230287437A1 (en) * 2020-06-05 2023-09-14 Modernatx, Inc. Bacterial strains for dna production
KR20230098825A (ko) 2020-11-04 2023-07-04 엘리고 바이오사이언스 씨. 아크네스 개체군에게 dna 페이로드의 원위치 전달을 위한 파지-유래 입자
EP4399316A4 (en) * 2021-09-08 2025-11-12 Broad Inst Inc MODIFIED FORMS FOR TARGETING THE CENTRAL NERVOUS SYSTEM AND MUSCLES
CN114032313B (zh) * 2021-11-18 2024-09-17 广东海洋大学 一种评估、检测和/预测耗牛的牛肉品质性状的方法
EP4516310A1 (en) * 2022-04-28 2025-03-05 The University of Tokyo Bacteriolytic agent against enterococcus faecalis
EP4662323A2 (en) * 2023-02-09 2025-12-17 Kate Therapeutics, Inc. Muscle targeted capsids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013893A1 (en) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Peptide nucleic acids having antibacterial activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
CA2269658A1 (en) * 1996-11-13 1998-05-22 Qbi Enterprises, Ltd. Gene identification method
AU735444B2 (en) * 1997-05-06 2001-07-05 Human Genome Sciences, Inc. (Enterococcus faecalis) polynucleotides and polypeptides
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6171838B1 (en) * 1997-08-13 2001-01-09 Smithkline Beecham Corporation ratB
US20020115217A1 (en) * 1997-10-02 2002-08-22 Smithkline Beecham Corporation Whole cell assay
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
JP2002524069A (ja) * 1998-09-09 2002-08-06 ミレニアム ファーマシューティカルズ インク． 必須細菌遺伝子およびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013893A1 (en) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Peptide nucleic acids having antibacterial activity

Also Published As

Publication number Publication date
WO2001070955A3 (en) 2002-08-01
KR20020097200A (ko) 2002-12-31
WO2001070955A8 (en) 2004-04-15
WO2001070955A2 (en) 2001-09-27
EP1268774A2 (en) 2003-01-02
US20020061569A1 (en) 2002-05-23
CA2404260A1 (en) 2001-09-27
AU2001249345A1 (en) 2001-10-03
JP2004516805A (ja) 2004-06-10

Similar Documents

Publication Publication Date Title
JP4852211B2 (ja) 原核生物における必須遺伝子の同定
US20040029129A1 (en) Identification of essential genes in microorganisms
WO2002077183A2 (en) Identification of essential genes in microorganisms
Gallagher et al. c-di-GMP arms an anti-σ to control progression of multicellular differentiation in Streptomyces
Ng et al. Regulation of the pspA virulence factor and essential pcsB murein biosynthetic genes by the phosphorylated VicR (YycF) response regulator in Streptococcus pneumoniae
JP2003518386A (ja) 大腸菌の増殖に必要であることが同定された遺伝子
US6720139B1 (en) Genes identified as required for proliferation in Escherichia coli
JP2002535007A (ja) Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉの増殖に必要であると同定された遺伝子
Buensuceso et al. The conserved tetratricopeptide repeat-containing C-terminal domain of Pseudomonas aeruginosa FimV is required for its cyclic AMP-dependent and-independent functions
WO2002103513A1 (en) Essential and important genes of pseudomonas aeruginosa and the use thereof to design or identify antibacterial agents
WO2007075177A2 (en) Antibiotics targeting mreb
US6589738B1 (en) Genes essential for microbial proliferation and antisense thereto
US20050026189A1 (en) Microbial operons
US20030170694A1 (en) Stabilized nucleic acids in gene and drug discovery and methods of use
EP1178052A2 (en) Genes identified as required for proliferation in Escherichia coli
Zhou et al. Variability of the tandem repeat region of the Escherichia coli tolA gene
Markley et al. An Escherichia coli-based bioengineering strategy to study streptolysin S biosynthesis
Choi et al. A HigB-like toxin promotes non-replicating Salmonella inside macrophages by inhibiting ribonuclease III
Wang Exploring the role of PilY1 family proteins in natural transformation
JP2002541819A (ja) 新規の必須細菌遺伝子およびこれらのタンパク質
JP2004528846A (ja) 細胞増殖を阻害する化合物の標的を特定する方法
US7390620B2 (en) Screening method for anti-microbial drug targets by genome-saturating mutagenesis (GSM)
CA2445687C (en) Compositions, methods and systems for the discovery of enediyne natural products
Camara et al. Initiation of chromosomal replication
Bakshi et al. Signature-Tagged Mutagenesis

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110927

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111024

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141028

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees